Assessment of and Interventions for Women at High Risk for Breast or Ovarian Cancer: A Survey of Primary Care Physicians

被引:8
作者
Samimi, Goli [1 ]
Heckman-Stoddard, Brandy M. [1 ]
Holmberg, Christine [2 ]
Tennant, Bethany [3 ]
Sheppard, Bonny Bloodgood [3 ]
Coa, Kisha, I [3 ]
Kay, Shelley S. [3 ]
Ford, Leslie G. [1 ]
Szabo, Eva [1 ]
Minasian, Lori M. [1 ]
机构
[1] NCI, Div Canc Prevent, Bethesda, MD 20872 USA
[2] Brandenburg Med Sch Theodor Fontane, Inst Social Med & Epidemiol, Brandenburg, Havel, Germany
[3] ICF, Fairfax, VA USA
关键词
INCREASE RECOMMENDATION; COLORECTAL CANCERS; SYSTEMATIC REVIEWS; DECISION-MAKING; FOLLOW-UP; PREVENTION; TAMOXIFEN; RALOXIFENE; CHEMOPREVENTION; REDUCTION;
D O I
10.1158/1940-6207.CAPR-20-0407
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
As clinical guidelines for cancer prevention refer individuals to primary care physicians (PCP) for risk assessment and clinical management, PCPs may be expected to play an increasing role in cancer prevention. It is crucial that PCPs are adequately supported to assess an individual's cancer risk and make appropriate recommendations. The objective of this study is to assess use, familiarity, attitude, and behaviors of PCPs regarding breast and ovarian cancer risk and prevention, to better understand the factors that influence their prescribing behaviors. We conducted a cross-sectional, web-based survey of PCPs in the United States, recruited from an opt-in healthcare provider panel. Invitations were sent in batches until the target sample size of 750 respondents (250 each for obstetrics/gynecology, internal medicine, and family medicine) was met. Self-reported use of breast/ovarian cancer risk assessments was low (34.7%-59.2%) compared with discussion of cancer family history (96.9%), breast exams (87.1%), and mammograms (92.8%). Although most respondents (48.0%-66.8%) were familiar with cancer prevention interventions, respondents who reported to be less familiar were more likely to report cautious attitudes. When presented with hypothetical cases depicting patients at different breast/ovarian cancer risks, up to 34.0% of respondents did not select any of the clinically recommended course(s) of action. This survey suggests that PCP use of breast/ovarian cancer risk assessment tools and ability to translate the perceived risks to clinical actions is variable. Improving implementation of cancer risk assessment and clinical management guidelines within primary care may be necessary to improve the appropriate prescribing of cancer prevention interventions. Prevention Relevance: Primary care physicians are becoming more involved in cancer prevention management, so it is important that cancer risk assessment and medical society guideline recommendations for cancer prevention are better integrated into primary care to improve appropriate prescribing of cancer prevention interventions and help reduce cancer risk.
引用
收藏
页码:185 / 194
页数:10
相关论文
共 48 条
  • [11] Deciding on breast cancer risk reduction: The role of counseling in individual decision-making - A qualitative study
    Blakeslee, Sarah B.
    McCaskill-Stevens, Worta
    Parker, Patricia A.
    Gunn, Christine M.
    Bandos, Hanna
    Bevers, Therese B.
    Battaglia, Tracy A.
    Fagerlin, Angela
    Mueller-Nordhorn, Jacqueline
    Holmberg, Christine
    [J]. PATIENT EDUCATION AND COUNSELING, 2017, 100 (12) : 2346 - 2354
  • [12] How do we increase uptake of tamoxifen and other anti-estrogens for breast cancer prevention?
    Crew, Katherine D.
    Albain, Kathy S.
    Hershman, Dawn L.
    Unger, Joseph M.
    Lo, Shelly S.
    [J]. NPJ BREAST CANCER, 2017, 3
  • [13] The effect of raloxifene on risk of breast cancer in postmenopausal women - Results from the MORE randomized trial
    Cummings, SR
    Eckert, S
    Krueger, KA
    Grady, D
    Powles, TJ
    Cauley, JA
    Norton, L
    Nickelsen, T
    Bjarnason, NH
    Morrow, M
    Lippman, ME
    Black, D
    Glusman, JE
    Costa, A
    Jordan, VC
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (23): : 2189 - 2197
  • [14] Long-term results of tamoxifen prophylaxis for breast cancer-96-month follow-up of the randomized IBIS-I trial
    Cuzick, Jack
    Forbes, John F.
    Sestak, Ivana
    Cawthorn, Simon
    Hamed, Hisham
    Holli, Kaija
    Howell, Anthony
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2007, 99 (04): : 272 - 282
  • [15] NCCN: Continuing Education
    Daly, Mary B.
    Pilarski, Robert
    Yurgelun, Matthew B.
    Berry, Michael P.
    Buys, Saundra S.
    Dickson, Patricia
    Domchek, Susan M.
    Elkhanany, Ahmed
    Friedman, Susan
    Garber, Judy E.
    Goggins, Michael
    Hutton, Mollie L.
    Khan, Seema
    Klein, Catherine
    Kohlmann, Wendy
    Kurian, Allison W.
    Laronga, Christine
    Litton, Jennifer K.
    Mak, Julie S.
    Menendez, Carolyn S.
    Merajver, Sofia D.
    Norquist, Barbara S.
    Offit, Kenneth
    Pal, Tuya
    Pederson, Holly J.
    Reiser, Gwen
    Shannon, Kristen Mahoney
    Visvanathan, Kala
    Weitzel, Jeffrey N.
    Wick, Myra J.
    Wisinski, Kari B.
    Dwyer, Mary A.
    Darlow, Susan D.
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2020, 18 (04): : 380 - 391
  • [16] DAVIS DA, 1995, JAMA-J AM MED ASSOC, V274, P700
  • [17] Modifiers of Cancer Risk in BRCA1 and BRCA2 Mutation Carriers: Systematic Review and Meta-Analysis
    Friebel, Tara M.
    Domchek, Susan M.
    Rebbeck, Timothy R.
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2014, 106 (06):
  • [18] Exemestane for Breast-Cancer Prevention in Postmenopausal Women
    Goss, Paul E.
    Ingle, James N.
    Ales-Martinez, Jose E.
    Cheung, Angela M.
    Chlebowski, Rowan T.
    Wactawski-Wende, Jean
    McTiernan, Anne
    Robbins, John
    Johnson, Karen C.
    Martin, Lisa W.
    Winquist, Eric
    Sarto, Gloria E.
    Garber, Judy E.
    Fabian, Carol J.
    Pujol, Pascal
    Maunsell, Elizabeth
    Farmer, Patricia
    Gelmon, Karen A.
    Tu, Dongsheng
    Richardson, Harriet
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (25) : 2381 - 2391
  • [19] Screening for Ovarian Cancer US Preventive Services Task Force Recommendation Statement
    Grossman, David C.
    Curry, Susan J.
    Owens, Douglas K.
    Barry, Michael J.
    Davidson, Karina W.
    Doubeni, Chyke A.
    Epling, John W., Jr.
    Kemper, Alex R.
    Krist, Alex H.
    Kurth, Ann E.
    Landefeld, Seth
    Mangione, Carol M.
    Phipps, Maureen G.
    Silverstein, Michael
    Simon, Melissa A.
    Tseng, Chien-Wen
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2018, 319 (06): : 588 - 594
  • [20] Barriers and facilitators to implementing cancer prevention clinical decision support in primary care: a qualitative study
    Harry, Melissa L.
    Truitt, Anjali R.
    Saman, Daniel M.
    Henzler-Buckingham, Hillary A.
    Allen, Clayton I.
    Walton, Kayla M.
    Ekstrom, Heidi L.
    O'Connor, Patrick J.
    Sperl-Hillen, JoAnn M.
    Bianco, Joseph A.
    Elliott, Thomas E.
    [J]. BMC HEALTH SERVICES RESEARCH, 2019, 19 (1)